Keyphrases
Biological Basis
100%
Melanoma Differentiation-associated gene-7
100%
IL-24
100%
Antitumor Properties
100%
Historical Perspective
100%
Tumor Cells
18%
Gene Therapy
9%
Adenovirus
9%
Chemotherapy
9%
Phase I Clinical Trial
9%
Autocrine Regulation
9%
Induced Apoptosis
9%
Radiotherapy
9%
Metastatic Melanoma
9%
Unique Properties
9%
Antiangiogenic Activity
9%
Antitumor
9%
Interleukin-10 Gene
9%
Terminal Differentiation
9%
Primary Cancer
9%
Advanced Cancer
9%
Gene Family
9%
Immune Regulation
9%
Clinical Activity
9%
Chromosomal Location
9%
Intratumoral Injection
9%
Hybrid Method
9%
Therapeutic Monoclonal Antibody
9%
Conserved Structures
9%
Advanced Solid Tumors
9%
Chemoprevention
9%
Incompetence
9%
Human Melanoma
9%
Human Tumor Xenograft
9%
Therapy Models
9%
Differentiation Therapy
9%
Xenograft Studies
9%
Suppression Subtractive Hybridization
9%
Bystander Antitumor Activity
9%
Medicine and Dentistry
Interleukin 24
100%
Melanoma
100%
Tumor Cell
16%
Cytokine
8%
In Vitro
8%
Clinical Trial
8%
Cancer
8%
Primary Tumor
8%
Chemoprophylaxis
8%
Advanced Cancer
8%
Programmed Cell Death
8%
Antineoplastic Activity
8%
Antiangiogenic Activity
8%
Interleukin 10
8%
Adenoviridae
8%
Chromosome Structure
8%
Multigene Family
8%
Intratumoral Drug Administration
8%
Metastatic Melanoma
8%
Tumor Xenograft
8%
Monoclonal Antibody Therapy
8%
Differentiation Therapy
8%
Radiation Therapy
8%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Interleukin 24
100%
Neoplasm
25%
Clinical Trial
8%
Cytokine
8%
Primary Tumor
8%
Chemotherapy
8%
Adenoviridae
8%
Monoclonal Antibody
8%
Antitumor Activity
8%
Antiangiogenic
8%
Interleukin 10
8%
Advanced Cancer
8%
Metastatic Melanoma
8%
Immunology and Microbiology
Interleukin 24
100%
Tumor Cell
25%
Cytokine
12%
Antineoplastic Activity
12%
Xenograft
12%
Interleukin 10
12%
Adenoviridae
12%
Chromosome Structure
12%
Multigene Family
12%
Monoclonal Antibody Therapy
12%
Antiangiogenic Activity
12%
Programmed Cell Death
12%
Biochemistry, Genetics and Molecular Biology
Interleukin 24
100%
Cytokine
12%
Clinical Trial
12%
Antineoplastic Activity
12%
Adenoviridae
12%
Multigene Family
12%
Antiangiogenic Activity
12%
Chromosome Structure
12%
Interleukin 10
12%
Monoclonal Antibody Therapy
12%
Programmed Cell Death
12%